LON:MXCT MaxCyte (MXCT) Share Price, News & Analysis GBX 1.43 -0.04 (-2.72%) As of 10/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesNews and Trends About MaxCyte Stock (LON:MXCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MaxCyte alerts:Sign Up Key Stats Today's Range 1.43▼ 1.5150-Day Range 0.96▼ 1.4752-Week Range 147.69▼ 407.84Volume1.02 million shsAverage Volume42,065 shsMarket Capitalization£1.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions. Let’s Build Better Cells Together. To learn more, please visit www.maxcyte.com Read More Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MXCT Stock News HeadlinesMaxCyte (LON:MXCT) Stock Price Breaks Below 50 Day Moving Average - Here's WhyOctober 17, 2026 | americanbankingnews.comMaxCyte stock surges 25% on raised 2026 revenue guidanceOctober 15, 2026 | au.finance.yahoo.comYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 24 at 1:00 AM | Profits Run (Ad)MaxCyte reiterates $30M-$32M 2026 revenue outlook as Genentech partnership expands enterprise modelAugust 13, 2026 | seekingalpha.comMaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ...August 13, 2026 | finance.yahoo.comCraig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)June 19, 2026 | theglobeandmail.comMaxCyte Shareholders Reelect Directors and Ratify AuditorJune 17, 2026 | tipranks.comMaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...May 13, 2026 | finance.yahoo.comSee More Headlines MXCT Stock Analysis - Frequently Asked Questions How have MXCT shares performed this year? MaxCyte's stock was trading at GBX 1.58 on January 1st, 2026. Since then, MXCT shares have decreased by 9.5% and is now trading at GBX 1.43. How do I buy shares of MaxCyte? Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of MaxCyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include ARK Innovation ETF (ARKK), Caribou Biosciences (CRBU), Editas Medicine (EDIT), ImmunityBio (IBRX), Intellia Therapeutics (NTLA), Tesla (TSLA) and Walt Disney (DIS). Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolLON:MXCT CIKN/A Webwww.maxcyte.com Phone+1-301-9441700FaxN/AEmployees80Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£45.08 million Net Margins-106.29% Pretax MarginN/A Return on Equity-18.73% Return on Assets-11.07% Debt Debt-to-Equity Ratio8.74 Current Ratio10.88 Quick Ratio14.38 Sales & Book Value Annual Sales£32.29 million Price / Sales0.05 Cash FlowGBX 0.73 per share Price / Cash Flow1.97 Book ValueGBX 203.85 per share Price / Book0.01Miscellaneous Outstanding Shares106,319,000Free FloatN/AMarket Cap£1.52 million OptionableNot Optionable Beta1.13 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (LON:MXCT) was last updated on 10/22/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MaxCyte With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
